Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.54 |
| ▸ | CDC25B | P30305 | 1/20 | 0.53 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9243497 | 0.85 | CA2 (0.49) | PKMSMN1; SMN2GLO1POLBCA12 | |
| SCHEMBL1802590 | 0.85 | ALDH1A1 (0.55) | PKMSMN1; SMN2GLO1CA12CA1 | |
| SCHEMBL1050351 | 0.85 | PKM (0.58) | PKMSMN1; SMN2GLO1CDC25BNEU3 | |
| SCHEMBL1802587 | 0.84 | GLO1 (0.46) | PKMSMN1; SMN2GLO1POLBCA12 | |
| SCHEMBL942127 | 0.84 | GLO1 (0.46) | PKMSMN1; SMN2GLO1CA12CA1 | |
| SCHEMBL6293695 | 0.83 | SMN1; SMN2 (0.59) | PKMSMN1; SMN2CDC25BPOLBNSD2 | |
| SCHEMBL2782333 | 0.83 | SMN1; SMN2 (0.59) | PKMSMN1; SMN2CDC25BPOLBNSD2 | |
| SCHEMBL31401059 | 0.83 | SMN1; SMN2 (0.59) | PKMSMN1; SMN2CDC25BPOLBNSD2 | |
| SCHEMBL13543252 | 0.82 | PKM (0.47) | PKMSMN1; SMN2GLO1CA12CA1 | |
| SCHEMBL940404 | 0.81 | SMN1; SMN2 (0.58) | PKMSMN1; SMN2CDC25BPOLBNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| CN-102036953-B | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20100009973-A1 | Integrase Inhibitors 3 | AVEXA LIMITED (AU) | 2010-01-14 | — | — | US | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2008157330-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| CN-100371328-C | Substituted benzoyl carbamidine derivative, its preparation method and medical uses | UNIV CHINA PHARMA (CN) | 2008-02-27 | — | — | CN | disclosed |
| WO-2007124546-A1 | INTEGRASE INHIBITORS 3 | AVEXA LIMITED (AU) | 2007-11-08 | — | — | WO | disclosed |
| CN-1803776-A | Substituted benzoyl carbamidine derivative, its preparation method and medical uses | UNIV CHINA PHARMA (CN) | 2006-07-19 | — | — | CN | disclosed |
| US-4302241-A | N-(PYRIMIDIN-2-YL-AMINOCARBONYL) ARYL SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-11-24 | — | — | US | disclosed |
| US-4125614-A | DIURETIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-11-14 | — | — | US | disclosed |
| US-4061761-A | Thiazolidine derivatives | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | MMP11, MMP10, MMP9 | PKM 1454/4885SMN1; SMN2 1506/4885GLO1 2707/4885 |
| US-20100009973-A1 | Integrase Inhibitors 3 | TYMP, IMPDH1, IMPDH2 | PKM 2377/4885SMN1; SMN2 1867/4885GLO1 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.